Navigation Links
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
Date:2/3/2009

3-200-3372 (international), conference ID# 84164912. To access the live audio webcast of the conference call, please log on to the investor relations page of the company's website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 84164912.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY and a research program focused on small molecules for the treatment of pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche, its development partner) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as
'/>"/>

SOURCE InterMune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at J.P. Morgan Healthcare Conference
2. InterMune to Present at Deutsche Bank Biotech Boston Confab
3. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
4. InterMune to Release Third Quarter 2008 Financial Results on November 6
5. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
6. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
7. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. InterMune to Present at BMO Healthcare Conference
11. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... (PRWEB) July 24, 2014 The first ... Dose Escalation in First in Human Studies” will cover ... better go/no-go decisions. , With increasing R&D costs and ... companies need to maximize the knowledge collected in early ... and improve success in late stage development. , Next, ...
(Date:7/24/2014)...   Cypher Genomics, Inc., the genome ... Adam Simpson as president and chief operating ... annotation and interpretation of individual human genomes for ... technology has the potential to play a transformative ... optimizing therapeutic approaches and reducing adverse drug reactions," ...
(Date:7/23/2014)... NEW YORK , July 24, 2014 /PRNewswire/ ... and Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX ... "IMNP."; "Immune" or "the Company"), announced a collaboration ... bullous pemphigoid last night at an event attended ... other interested parties. Lyfebulb is a health and ...
(Date:7/23/2014)... made great strides in saving China,s endangered national treasure, ... 65 giant panda reserves that have been established and ... 1596 pandas remain in the wild. , Breeding ... the panda by improving genetic diversity, avoid inbreeding and ... are these high-profile programs doing so far? , In ...
Breaking Biology Technology:Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5
... Key words: ... Imaging Beads, , ... pro-inflammatory cytokines with potent leukocyte activation and/or chemotactic activity in ... C, and CXC3) based on the number and sequential relationship of ...
... J. Chartier and H.C. Birnboim , DNA Genotek Inc., ... DNA collected with Oragene works well with TaqMan SNP Genotyping Assays. , ... detected., , ... Single-nucleotide polymorphisms (SNPs) are highly abundant, and are estimated , ...
... , , ... Research Organics, Inc.is an ISO 9001:2000 primary manufacturer and leading ... for molecular biology, , diagnostics, cell culture, ... , Founded in 1953, Research Organics pioneered manufacture ...
Cached Biology Technology:The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 2The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 3The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 4Oragene is compatible with TaqMan SNP genotyping 2Oragene is compatible with TaqMan SNP genotyping 3Research Organics 2Research Organics 3
(Date:7/24/2014)... has its own microbial terroir, meaning the microbial populations ... in the product, creating the final flavor according to ... Applied and Environmental Microbiology . This is the first ... sake brewery. , Many sake makers inoculate with ... Mills of the University of California, Davis, but he ...
(Date:7/24/2014)... similar counterparts in humans, affect the connections between nerve ... the hippocampus, an area of the brain that plays ... of memories. The results of the study have been ... function depends on the active communication between nerve cells, ... together into a dense network where they constantly relay ...
(Date:7/24/2014)... 24, 2014) For years, researchers and patients have ... any cell type in the bodycould provide insight into ... Yet progress has been hampered by the inability to ... their human counterparts, in part because human ESCs are ... , Now Thorold Theunissen, Benjamin Powell, and Haoyi Wang, ...
Breaking Biology News(10 mins):The microbes make the sake brewery 2A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2
... dark scene, attention brings to mind specific details of our ... at the Salk Institute for Biological Studies shows that the ... for its role in the control of eye and head ... findings, published in the Dec. 20, 2009, issue of the ...
... in an antibiotic-resistant bacterium is cause for concern, according ... Faculty of 1000 member Dr Johann Pitout, of ... Calgary, urges the medical community to monitor the spread ... to use more powerful antibiotics as a first response. ...
... UCLA scientists have identified a molecular switch that prevents ... 24 edition of the journal Neuron , the discovery ... ultimately leads to death in as little as 10 years. ... Americans, Huntington,s progressively deprives patients of their ability to walk, ...
Cached Biology News:Seeing without looking 2UCLA scientists find molecular switch to prevent Huntington's disease in mice 2
RNase-Free DNase 50 l...
Request Info...
... is a DNA-dependent RNA polymerase which is ... It efficiently synthesizes in vitro transcripts from ... from a T7 promoter. Transcripts can ... in vitro translation, substrates in RNA processing ...
... in a 3'-> 5' direction from a ... of single-stranded DNA. Under defined reaction conditions, ... a uniform rate yielding predictable and reproducible ... of deoxyribonucleotides by Exonuclease III is dependent ...
Biology Products: